Statements (23)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:CEO |
gptkb:Jeong_Shin
|
| gptkbp:country |
gptkb:South_Korea
|
| gptkbp:focusArea |
oncology
central nervous system disorders |
| gptkbp:founded |
1993
|
| gptkbp:headquarters_location |
gptkb:Seongnam,_South_Korea
|
| https://www.w3.org/2000/01/rdf-schema#label |
SK Biopharmaceuticals
|
| gptkbp:industry |
pharmaceuticals
|
| gptkbp:IPODate |
2020
|
| gptkbp:languageOfService |
gptkb:Korean
|
| gptkbp:notableProduct |
gptkb:Cenobamate
gptkb:Solriamfetol |
| gptkbp:numberOfEmployees |
about 300 (2023)
|
| gptkbp:parentOrganization |
gptkb:SK_Group
|
| gptkbp:researchArea |
epilepsy
sleep disorders |
| gptkbp:stockExchange |
gptkb:KRX
|
| gptkbp:stockSymbol |
326030
|
| gptkbp:subsidiary |
gptkb:SK_Life_Science,_Inc.
|
| gptkbp:website |
https://www.skbiopharm.com
|
| gptkbp:bfsParent |
gptkb:SK_Group
|
| gptkbp:bfsLayer |
5
|